BIOLINERX     Print Page  Close Window

SEC filings
6-K
BIOLINERX LTD. filed this Form 6-K on 04/05/2017
Entire Document
 

 

 

Item 8.01 Other Events.

 

BioLineRx Ltd. (the “Company”) announced today that on April 5, 2017 it closed its previously announced underwritten public offering of approximately 33.8 million American Depositary Shares (“ADSs”), each representing one (1) of its ordinary shares, at a public offering price of $0.85 per ADS. The Company received gross proceeds of $28.75 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by BioLineRx, which it expects to use to fund a number of clinical trials, including for BL-8040 and AGI-134, and for working capital and general corporate purposes. A copy of the press release announcing the closing of the transaction is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

In connection with the issuance of the ADSs, on March 31, 2017, the Company entered into an Underwriting Agreement (the “Underwriting Agreement”) with the underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell the ADSs to the Underwriters. For a complete description of the terms and conditions of the Underwriting Agreement, please refer to such agreement, which is incorporated herein by reference and attached to this report as Exhibit 1.1.

 

On April 5, 2017, Yigal Arnon & Co. issued its opinion, a copy of which is filed as Exhibit 5.1 to this report, with respect to the legality of the issuance by the Company of the ordinary shares underlying the ADSs sold pursuant to the prospectus and the related prospectus supplement filed by the Company with the U.S. Securities and Exchange Commission (“SEC”) on April 3, 2017.

 

On April 5, 2017, Morrison & Foerster LLP issued its opinion, a copy of which is filed as Exhibit 5.2 to this report, with respect to the legality of the sale by the Company of the ADSs sold pursuant to the prospectus and the related prospectus supplement filed by the Company with the SEC on April 3, 2017.

 

Item 9.01 Financial Statements and Exhibits.

 

(d)Exhibits

 

The following exhibits are filed as part of this report:

 

Exhibit No.   Description of Exhibit
1.1   Underwriting Agreement, dated March 31, 2017
5.1   Opinion of Yigal Arnon & Co., Israeli Counsel to the Company
5.2   Opinion of Morrison & Foerster LLP, U.S. Counsel to the Company
99.1   Press release dated April 5, 2017